VEGFA Mouse mAb - Primary antibody, specific to VEGFA, Mouse IgG1

    Application:
  • Capture Antibody
  • CLIA
  • ELISA
Features and benefits
  • Host species: Mouse
  • Species reactivity(Reacts with): Human
  • Isotype: Mouse IgG1
  • Clone Number: 12A4-7
  • Conjugation: Unconjugated
Item Number
Ab134085
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab134085-10μg
10μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$66.90
Ab134085-50μg
50μg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$199.90
Ab134085-100μg
100μg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$299.90
Ab134085-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,799.90

mAb(12A4-7); Mouse anti Human VEGFA Antibody; Capture Antibody, ELISA, CLIA; Unconjugated

Basic Description

Product NameVEGFA Mouse mAb - Primary antibody, specific to VEGFA, Mouse IgG1
SynonymsFolliculostellate cell-derived growth factor antibody | Glioma-derived endothelial cell mitogen antibody | MGC70609 antibody | MVCD1 antibody | Vascular endothelial growth factor A antibody | vascular endothelial growth factor A121 antibody | vascular end
Specifications & PurityExactAb™, Validated, Carrier Free, Azide Free, Lot by Lot
Host speciesMouse
SpecificityVEGFA
ImmunogenRecombinant Human VEGF Protein, C-His tag
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Validated
Product Description

Mouse anti Human VEGFA Antibody, Monoclonal (12A4-7), is a Capture antibody could be used for ELISA, CLIA.
CLIA: 20µg/2mg magnetic beads

Product Properties

IsotypeMouse IgG1
Light Chain Typekappa
SDS-PAGE28.6 kDa (Light Chain) & 51.1 kDa (Heavy Chain), under reducing conditions; 181.0 kDa, under non-reducing conditions.
Purification MethodAffinity chromatography
Matched Pairs[Ab134091] VEGFA Mouse mAb as Detection antibody in ELISA, CLIA
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -20°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at 37°C short term (7 days). Store at 4°C short term (30 days). Store at -20±5°C long term (36 months). Upon delivery aliquot. Avoid freeze/thaw cycle.

Images

Relevance of detection results between aladdin Antibody Pair (Ab134085 & Ab134091) and Competitor company in CLIA
·Capture antibody: VEGFA Mouse mAb (Ab134085)
·Detection antibody: VEGFA Mouse mAb (Ab134091)

Associated Targets(Human)

VEGFA Tclin Vascular endothelial growth factor A (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Application

ApplicationDilution info
CLIA

20µg/2mg magnetic beads

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

2 results found

Lot NumberCertificate TypeDateItem
ZJ23F1001298Certificate of AnalysisOct 13, 2023 Ab134085
ZJ23F1001299Certificate of AnalysisOct 13, 2023 Ab134085

Related Documents

References

1. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V.  (2005)  Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration..  Invest Ophthalmol Vis Sci,  46  (2): (726-33).  [PMID:15671306] [10.1021/op500134e]
2. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM.  (1997)  Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site..  Proc Natl Acad Sci USA,  94  (14): (7192-7).  [PMID:9207067] [10.1021/op500134e]
3. Johnstone KD, Karoli T, Liu L, Dredge K, Copeman E, Li CP, Davis K, Hammond E, Bytheway I, Kostewicz E et al..  (2010)  Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth..  J Med Chem,  53  (4): (1686-99).  [PMID:20128596] [10.1021/op500134e]
4. Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J et al..  (2016)  Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases..  EMBO Mol Med,  (11): (1265-1288).  [PMID:27742718] [10.1021/op500134e]
5. Chen QY, Liu Y, Cai W, Luesch H..  (2014)  Improved total synthesis and biological evaluation of potent apratoxin S4 based anticancer agents with differential stability and further enhanced activity..  J Med Chem,  57  (7): (3011-3029).  [PMID:24660812] [10.1021/jm4019965]
6. Weindel, K K, Marmé, D D and Weich, H A HA..  (1992)  AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor..  Biochemical and biophysical research communications,    (31):   [PMID:1567395]
7. Tischer, E E and 6 more authors..  (1991)  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing..  The Journal of biological chemistry,    (25):   [PMID:1711045]
8. Houck, K A KA and 5 more authors..  (1991)  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA..  Molecular endocrinology (Baltimore, Md.),      [PMID:1791831]
9. Leung, D W DW, Cachianes, G G, Kuang, W J WJ, Goeddel, D V DV and Ferrara, N N..  (1989)  Vascular endothelial growth factor is a secreted angiogenic mitogen..  Science (New York, N.Y.),    (8):   [PMID:2479986]
10. Keck, P J PJ and 6 more authors..  (1989)  Vascular permeability factor, an endothelial cell mitogen related to PDGF..  Science (New York, N.Y.),    (8):   [PMID:2479987]
11. Connolly, D T DT and 8 more authors..  (1989)  Human vascular permeability factor. Isolation from U937 cells..  The Journal of biological chemistry,    (25):   [PMID:2584205]
12. Fiebich, B L BL and 8 more authors..  (1993)  Synthesis and assembly of functionally active human vascular endothelial growth factor homodimers in insect cells..  European journal of biochemistry,    (15):   [PMID:7678805]
13. Poltorak, Z Z and 7 more authors..  (1997)  VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix..  The Journal of biological chemistry,    (14):   [PMID:9054410]
14. Fairbrother, W J WJ, Champe, M A MA, Christinger, H W HW, Keyt, B A BA and Starovasnik, M A MA..  (1997)  1H, 13C, and 15N backbone assignment and secondary structure of the receptor-binding domain of vascular endothelial growth factor..  Protein science : a publication of the Protein Society,      [PMID:9336848]
15. Muller, Y A YA, Christinger, H W HW, Keyt, B A BA and de Vos, A M AM..  (1997)  The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding..  Structure (London, England : 1993),    (15):   [PMID:9351807]
16. Claffey, K P KP and 7 more authors..  (1998)  Identification of a human VPF/VEGF 3' untranslated region mediating hypoxia-induced mRNA stability..  Molecular biology of the cell,      [PMID:9450968]
17. Fairbrother, W J WJ, Champe, M A MA, Christinger, H W HW, Keyt, B A BA and Starovasnik, M A MA..  (1998)  Solution structure of the heparin-binding domain of vascular endothelial growth factor..  Structure (London, England : 1993),    (15):   [PMID:9634701]
18. Lei, J J, Jiang, A A and Pei, D D..  (1998)  Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183..  Biochimica et biophysica acta,    (22):   [PMID:9878851]
19. Wiesmann, C C and 7 more authors..  (1998)  Crystal structure of the complex between VEGF and a receptor-blocking peptide..  Biochemistry,    (22):   [PMID:9922142]
20. Jingjing, L L, Xue, Y Y, Agarwal, N N and Roque, R S RS..  (1999)  Human Müller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor..  Investigative ophthalmology & visual science,      [PMID:10067980]
21. Whittle, C C, Gillespie, K K, Harrison, R R, Mathieson, P W PW and Harper, S J SJ..  (1999)  Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant..  Clinical science (London, England : 1979),      [PMID:10464055]
22. Murphy, J F JF and Fitzgerald, D J DJ..  (2001)  Vascular endothelial growth factor induces cyclooxygenase-dependent proliferation of endothelial cells via the VEGF-2 receptor..  FASEB journal : official publication of the Federation of American Societies for Experimental Biology,      [PMID:11427521]
23. Tee, M K MK and Jaffe, R B RB..  (2001)  A precursor form of vascular endothelial growth factor arises by initiation from an upstream in-frame CUG codon..  The Biochemical journal,    (1):   [PMID:11563986]
24. Huez, I I, Bornes, S S, Bresson, D D, Créancier, L L and Prats, H H..  (2001)  New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation..  Molecular endocrinology (Baltimore, Md.),      [PMID:11731620]
25. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ..  (2002)  TTD: Therapeutic Target Database..  Nucleic acids research,    (1):   [PMID:11752352]
26. Sasamura, H H and 7 more authors..  (2002)  Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma..  British journal of cancer,    (4):   [PMID:11875741]
27. Awata, Takuya T and 7 more authors..  (2002)  A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes..  Diabetes,      [PMID:11978667]
28. Bates, David O DO and 8 more authors..  (2002)  VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma..  Cancer research,    (15):   [PMID:12124351]
29. Bornes, Stéphanie S and 6 more authors..  (2004)  Control of the vascular endothelial growth factor internal ribosome entry site (IRES) activity and translation initiation by alternatively spliced coding sequences..  The Journal of biological chemistry,    (30):   [PMID:14764596]
30. Saijonmaa, Outi O, Nyman, Tuulikki T and Fyhrquist, Frej F..  (2004)  Carvedilol inhibits basal and stimulated ACE production in human endothelial cells..  Journal of cardiovascular pharmacology,      [PMID:15071347]
31. Yao, Jianhua S JS and 5 more authors..  (2004)  Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases..  Circulation research,    (20):   [PMID:15256478]
32. Zhang, Zemin Z and Henzel, William J WJ..  (2004)  Signal peptide prediction based on analysis of experimentally verified cleavage sites..  Protein science : a publication of the Protein Society,      [PMID:15340161]
33. Shyu, Kou-Gi KG and 5 more authors..  (2005)  Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure..  Journal of cardiac failure,      [PMID:15732037]
34. Rosenbaum-Dekel, Yifat Y and 6 more authors..  (2005)  Nuclear localization of long-VEGF is associated with hypoxia and tumor angiogenesis..  Biochemical and biophysical research communications,    (24):   [PMID:15896327]
35. Rocchetti, Romina R and 5 more authors..  (2005)  Antiangiogenic drugs for chemotherapy of bladder tumours..  Chemotherapy,      [PMID:16224178]
36. Dixelius, Johan J and 5 more authors..  (2006)  Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein..  Cancer research,    (15):   [PMID:16489009]
37. Rosenfeld, Philip J PJ, Rich, Ryan M RM and Lalwani, Geeta A GA..  (2006)  Ranibizumab: Phase III clinical trial results..  Ophthalmology clinics of North America,      [PMID:16935211]
38. Ferrara, Napoleone N, Damico, Lisa L, Shams, Naveed N, Lowman, Henry H and Kim, Robert R..  (2006)  Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration..  Retina (Philadelphia, Pa.),      [PMID:17031284]
39. Li, Ling L and Renier, Geneviève G..  (2006)  Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression..  Metabolism: clinical and experimental,      [PMID:17046555]
40. Glorioso, Nicola N and 8 more authors..  (2007)  Association of ATP1A1 and dear single-nucleotide polymorphism haplotypes with essential hypertension: sex-specific and haplotype-specific effects..  Circulation research,    (25):   [PMID:17446437]
41. Kimura, Tetsushi T and 5 more authors..  (2007)  Comparisons between the beneficial effects of different sulphonylurea treatments on ischemia-induced retinal neovascularization..  Free radical biology & medicine,    (1):   [PMID:17602961]
42. Marchetti, Marina M and 6 more authors..  (2008)  Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin..  Thrombosis research,      [PMID:17692905]
43. Dejneka, Nadine S; Wan, Shanhong; Bond, Ottrina S; Kornbrust, Douglas J and Reich, Samuel J..  (2008)  Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes..  Molecular vision,    (28):   [PMID:18523657]
44. Goshima, Naoki N and 54 more authors..  (2008)  Human protein factory for converting the transcriptome into an in vitro-expressed proteome,..  Nature methods,      [PMID:19054851]
45. Spitzer, Martin S; Ziemssen, Focke; Bartz-Schmidt, Karl U; Gelisken, Faik and Szurman, Peter..  (2008)  Treatment of age-related macular degeneration: focus on ranibizumab..  Clinical ophthalmology (Auckland, N.Z.),      [PMID:19668384]
46. Norrby, Klas and Nordenhem, Arvid..  (2010)  Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo..  APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,      [PMID:21091776]
47. Shan, B B and 9 more authors..  (2012)  RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells..  Endocrine-related cancer,      [PMID:22009797]
48. Browning, David J DJ, Kaiser, Peter K PK, Rosenfeld, Philip J PJ and Stewart, Michael W MW..  (2012)  Aflibercept for age-related macular degeneration: a game-changer or quiet addition?.  American journal of ophthalmology,      [PMID:22813448]
49. Khayati, Farah F and 13 more authors..  (2015)  EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF..  Oncotarget,      [PMID:25825981]
50. He, Weiwei W and 16 more authors..  (2015)  CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase..  Nature,    (29):   [PMID:26503042]
51. Han, Kelong K and 7 more authors..  (2016)  Population pharmacokinetics of bevacizumab in cancer patients with external validation..  Cancer chemotherapy and pharmacology,      [PMID:27329360]

Solution Calculators